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ing for a short time to reduce the radiation dose, as shown in 
Tables 3 and 4.
The data presented provide further information on the secre­
tion rate for 201T1 in breast milk and may be helpful in 
establishing safety guidelines for cases involving T1 admin­
istration to lactating patients.
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The isotopes 55Co and 57Co have been evaluated for PET and 
SPECT Imaging in several clinical brain studies. For clinical applica­
tion of cobalt, it is important to know the delivered radiation dose. 
The biodistribution of 55Co in both rat and humans after intravenous 
(boius)-administration was studied. Based on pharmacokinetic data, 
radiation dose calculations according to the MIRD system are 
presented. By combining present measurements with literature data 
on 60CoCI2. the radiation dose delivered by 56CoCI2 (T1/2 78.8 days) 
and 57CoCI2 (T1/2 = 270 days) could be assessed. Methods: 
Whole-body Co-PET was performed in two healthy volunteers and 
one rat after intravenous injection of 37 and 3.7 MBq (1 resp. 0.1 
mCi) 55Co, respectively. Blood samples were withdrawn during 300 
min in humans. In seven rats the 55Co-biodistribution was deter­
mined by postmortem analysis. The residence time of the liver 
(critical organ) was determined in rats and humans. Blood partition- 
data of 55Co were assessed resulting in basic pharmacokinetic data 
in humans. Based on these kinetic data, radiation dose was calcu­
lated using the MIRD protocol. Results: In both the humans and the 
rat, the liver and bladder retained the highest fractions of 55Co (about 
50% resp. 40% of the administered dose). The liver residence time 
in humans was 8.6 hr. The free fraction 55Co in the human plasma 
was at maximum 12%. The total-body mean transit time was 152 
min. The volume of the central compartment = 2.8 liter and the 
steady-state distribution volume = 48 liter. Conclusion: From these 
results, according to the WHO recommendations for class II studies,
22.2 MBq (0.6 mCi) 55Co and 14.8 MBq (0.4 mCi) 57Co (excluding 
any radionuclide contamination) can be used.
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In  the past, cobalt isotopes have been used for radiotherapy 
(60Co) and radio-diagnostic purposes (bleomycine-57Co) (1-4).
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Presently, the isotopes 55Co and 57Co are evaluated for brain 
imaging in several diseases, including stroke, brain trauma and 
multiple sclerosis (5-8).  These studies show the potency of 
cobalt to detect (small) brain lesions. Because of the limited 
availability of PET centers, we included both 55Co (PET- 
isotope; T 1/2 =  17.5 hr) and 57Co (SPECT-isotope; T 1/2 =  270 
days) in our study. Cobalt-5 5-PET has the advantage of high 
spatial resolution, absolute quantitation and a relative low 
radiation dose. The disadvantage is low availability for clinical 
routine application and logistical problems concerning the 
relatively short half-life. In contrast, 57Co-SPECT has the 
disadvantage of a lower spatial resolution, a lack of quantitative 
representation due to the impossibility of attenuation correction 
and a relatively high radiation dose. The advantage, however, is 
its wider availability and simple logistics due to a much longer 
half-life. Cobalt-55 is commonly produced by the 56Fe 
(p,2n)55Co nuclear reaction using natural iron as target 
material (5). Since the 56Fe(p,n)56Co reaction is unavoid- 
able, Co will always be present as a longer-lived contam­
ination (4,5).
For the clinical applications of these cobalt radionuclides, it 
is important to estimate the radiation dose to various tissues. To 
specify such dose commitments, knowledge of excretion, reten­
tion and distribution of cobalt in man is essential. Such 
information in man is limited, except that of cobalt as a complex 
in vitamin B )2 and bleomycine (1,9, JO). Virtually all available 
animal data on free (noncomplexed) cobalt were obtained with 
60Co in rats (9-16).
In the present study, the in vivo distribution of 55Co follow­
ing a (single) intravenous-bolus administration of 55Co was 
studied both in healthy volunteers and in rats. Cobalt-55 blood 
partition-data were determined. Data obtained from bio'distri- 
bution, in both rat and humans combined with basic pharma­
cokinetics of cobalt, were used to calculate the absorbed dose of 
CoCl2 according to the MIRD formulation (21).
a
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MATERIALS a n d  m e t h o d s  
Cobalt PET
Whole-body scans were made 0 -4 8  hr after the intravenous 
administration of 37 MBq (1 mCi) sterile 55CoC12. Contiguous 
scans were made and image reconstruction of 3.375-mm thick 
planes was done using standard software. The positron camera is 
calibrated in absolute terms and also cross calibrated with a Nal 
well counter for the measurement of blood samples. Cobalt-5 5  was 
produced by the 56Fe(p,2n)55Co nuclear reaction using a 27-MeV 
proton beam delivered by the AVF-cyclotron o f the Technical 
University of Eindhoven (2-5).  Purification and quality control 
have been described in detail elsewhere (2 - 5 ). The clinical use of 
55Co (T1/2 17.5 hr; 77% jS+) is limited due to the contamination 
with 56Co (T1/2 78.8 days; 19% J3+). The ratio 55Co versus 56Co 
depends on the energy of the proton beam and the target-thickncss 
used for production. Thus, the radiation dose of both 55CoCl2 and 
5()CoC12 must be assessed. Whole-body scans were made in two 
volunteers and one rat at various times after intravenous injection.
Animal Studies
Adult male Wistar rats (n =  7) were individually housed with ad 
libitum access to food and water. Each animal was first provided 
with a permanent Silicon catheter (0.95 mm o.d.; 0.50 mm i.d.) in 
the right atrium, inserted via the jugular vein (17). This method 
allows frequent blood-sampling in undisturbed, freely moving rats 
(17). The heart-catheter was permanently fixed to the back of the 
animal. A week after surgery, animals were injected with 3.7 MBq
c c
(0.1 mCi) Co through this catheter in a volume of 0.3 ml per 
animal (t =  0). One rat was anesthetized with pentobarbital (50 
mg/kg, ip) and PET scans were made at 0.5, 24 and 48 hr
JS £
postadministration (pa). Data were analyzed using ''Co liver- 
residue detection and expressed as arbitrary units (au) per pixel. 
Rats were killed at t — 55 hr. The counts per minute (cpm) per 
gram sample were determined in tissue o f decapitated animals 
using a scintillation counter. Tissue samples were taken of urine, 
kidney, lung, heart, testis, liver, pancreas, blood, spleen, stomach 
and skin. The animal experiments were approved by the Animal 
Ethics Committee of the Groningen University.
Healthy Volunteer Studies
Two healthy volunteers (male, age 26 -30  yr; 75 and 85 kg body 
weight) were injected intravenously with 37 MBq (1 mCi) 55CoC12. 
Of each volunteer three whole-body scans were made: the first 
immediately, the second at 24 hr and the third at 48 hr after 
injection. The data acquisition time was 3 min per position and the 
volunteer was scanned in two parts to cover the whole body. From 
the reconstructed transverse section images whole body anterior- 
posterior (AP) views were created using standard software. Blood 
samples were withdrawn at regular intervals, during 300 min 
following intravenous administration for 5Co-determination in 
blood, plasma and the free, cell and protein-bound fraction using 
dialysis or tri-chloric acid (TCA) precipitation. Sampling was 
performed using a radial-artery catheter during the first 60 min, 
followed by venous sampling. The study was approved by the 
hospital’s medical ethics committee and both subjects gave written 
informed consent.
Human Pharmacokinetics
Cobalt-55 levels were determined in whole blood and plasma. 
Blood-partition data (cell, protein-bound and free fraction) after a 
single intravenous bolus administration o f 37 MBq (1 mCi) 55Co 
were obtained. The free fraction was assessed using either dialysis 
(against phosphate buffered saline; vol:vol: 1 :1 0  and 1:1 0 0 ) or 
TCA-precipitation (equal volumes of plasma and TCA; and con­
centration of TCA 15%). Plasma concentration time curves o f two 
human volunteers were analyzed by using a nonlinear regression
program (18).  Data were weighted reciprocally and were fitted best 
according to a linear open two compartment mode). Applying 
statistical moment theory, basic pharmacokinetic parameters were 
calculated {19,20). The plasma-volume was calculated according 
to the empirical equation:
Vbioud -  0.417 (length in meters)3
-f- 0,045 (weight in kg-0,03) X 1000
Vplasnia Ht X Vklood 
with: Vbiood ~  blood volume (mi)
Vpiasma ” plasmavolume (ml)
Ht =  hematocrite.
Human Dosimetry
To determine the radiation dose of 55CoCl2 according to the 
MIRD protocol the residence times o f 55Co in the various organs 
have to be estimated (21 ). For the calculation of the radiation dose 
the M1RDOSE3 program was used (22). For pharmacokinetic 
reasons, only three source organs were considered: liver, bladder 
and gastro-intestinal (gi) tract (23-27). The liver is assumed to be 
the dose-limiting organ since 50% of the administered dose is 
accumulated in the liver. The time-activity curve o f the liver could 
be described by a monoexponential curve. From this monoexpo­
nential liver time-activity curve the Tcfr is determined, resulting in 
the liver biological half-life Tb according to:
T— ieff t : 1 +  t 1/2
with Tefr =  effective half-life (liver)
Tb =  biological half-life (liver)
Ti/2 = physical half-life.
From this established Tb and the known T 1/2 of 56Co and 57Co, 
Tefï o f 56Co and 57Co is calculated. Consequently, the liver 
residence time (TrtJS) can be calculated according:
A0 Tres = At dt
A = 0.5 A0 e"At 
A =  ln2
here A t =  Co activity in the liver at time t, A(J =  administered 
Co activity intravenously and A =  Co clearance rate from the 
liver.
input to the program were the calculated residence time in the 
liver (T*.*.) in combination with a dynamic bladder model according 
to the MIRD. A renal input fraction of 40% (based on rat data), a 
renal Tb (resulting in renal Tefr) and the assumption o f a voiding 
interval of 2.5 hr were used as input parameters for the bladder 
model. For the calculation of the radiation dose in the gi-tract an 
input fraction of 0.05 into the small intestine (based on rat data) 
was assumed. The MIRDOSE3 program provides three different 
estimates, the total body radiation dose (2 2 ), the effective dose 
(28) and the effective dose equivalent (29). The use of total body 
dose should be restricted to compounds with a rather homogeneous 
distribution and can only be used as a zero order approximation if 
no or too few pharmacokinetic parameters are known (30). For the 
calculation of the radiation doses of longer lived Co-isotopes 
(56Co; 57Co), the fact that a second longer lived compartment in the 
liver is present has to be taken into account. From measurements
C o b a l t  D o s im e t r y  a n d  P h a r m a c o k in e t ic s  • Jansen et al. 2083
rÍ
f '/ r i r v ^ V r rpr- 7* ■--.'” T r : r TV —> 1'
V¿,wy «v*/* *v. *'- *■•'1 * <■* V i U .r o » » v-r-r* fJ ÍIXW.I WJ »  1« <W-isP >.x I » ■ »• I - I r 1 X.Ï. > ; r.Ts-1r-.-I- - 1, ' . * - ■ - • - "  ■ ** I - - * ---
,'i<v I.
&WW»
I
/j
I
;
.■»
■JÄu«{
'<*N ira te»
.»r^ 1 iÄs«f
...— ,  c?
¿y ^  ^ i í i - ìjr^ .v'' siju
fWWWiÄtowe*
: J»Jrc^ 't--»c'r>>T-m'>V^ |—:ƒ *'riiyy>'-»>^ -y'>-jT->'r,.''T-T-T<'-,' ,/rJy-/>'>^ > >1:1 i W V J.Ci
v><r.»j»t¡o»
^r'Jioîie
-d I
->WW«N*
<PW1 JWH>
Vi t iF ^Í35&I©
muVniiVx
«M1
:<t)
ritti#
uftrffe
,vrt$*r A U lA
•o
«I
■V*
flWiWlWm»
-**>Wi»m»F}
jianw#»?/
■W.'W- VWU
*
'ÄflWf itf*
¡UfetfW
i#
•* #
*
«
*
■ < im» » «lm ij - .
**#* *
■*>
3
■W*l
•J>4»W.<*W
'«■»mW»**»**
•-.i i
.#>V
/ j , j y %.’>( ■{' ' '
m m m m & Ém »
TABLE 2
Radiation Dose Delivered by 55CoCI2, 56CoCI2 and 57CoCI, *
s5CoCI2
56CoCI2
Tracer Total body ED EDE
8.28E-2 (0.31) 1.39E-1 (5.1) 1.89E-1 (0.7)
55CoCI2 + bladder 8.43E-2 (0.31) 1.52E-1 (5.6) 1.97E-1 (0.73)
55CoCI2 + bladder + G! tract 9.16E-2 (0.34) 2.15E-1 (8.0) 2.36E-1 (0.87)
3.00E-1 (1.1) 4.56E-1 (1.7) 6.75E-1 (2.5)
56CoCI2 4- bladder 3.05E-1 (1.1) 4.79E-1 (1.8) 6.81 E-1 (2.5)
56CoCI2 + bladder + Gl tract 3.27E-1 (1.2) 6.18E-1 (2.3) 7.41 E-1 (2.7)
56CoCI2 + bladder + Gl tract, Tres = 137 hr 1 ,57E + 0 (5.8) 2.51 E 4- 0 (9.3) 3.54E -h 0(13-1)
57CoCI2 + bladder + Gl tract, Tres = 325 hr 2.02E-1 (0.75) 3.36E-1 (1.2) 4.65E-1 (1.7)
Parameters of the dynamic bladder mode! and gi model are as described in the text. Radiation dose is given as total body dose, effective dose (ED) 
according to ICRP 60 and effective dose equivalent (EDE) according to ICRP 30. All radiation doses are given in mGy/MBq (rem/mCi) as calculated by the 
MIRDOSE3 program.
mGy/MBq • s, the fraction of 50% and the residence time (8.6 
hr). From Table 2, it is obvious that the contribution of the 
cobalt excreted via kidneys, using the dynamic bladder model, 
to the radiation dose is rather limited. Variation in the input 
parameters of the dynamic bladder model did not imply any 
significant change in the radiation dose.
The contamination o f 55Co with 56Co is unavoidable, due to 
the production process. The amount of 56Co as percentage of 
total amount of Co-activity produced is dependent on the proton 
beam energy and the thickness of the target material. The 56Co 
contamination can be reduced drastically by using the 
54Fe(d,n)55Co or the 58Ni(p,a)55Co nuclear reaction at the cost 
of using enriched (rather expensive) 54Fe or 5SNi as a target 
material and at the cost of a reduced 55Co yield with respect to 
the proton induced reaction on 56Fe. Cobalt-57 is commercially 
available without any contamination.
We used a linear open two-compartment model to fit our 
pharmacokinetic cobalt data. Since the total-body mean transit 
time T is determined by both tU2a (initial phase) and tI/2 /3 
(elimination phase), and t1/2^  (1 min) is small compared to t1/2j3 
(123 min), the total body T (152 min) is in the same order of 
magnitude as t l/2tp (123 min), which purports cobalt excretion 
as the rate-limiting process. Moreover, V\ (volume of the 
central compartment; 2.8 liter) is in the same order of magni­
tude as the calculated plasma volume (3 liters) for our healthy 
volunteers. This suggests the plasma-compartment to be the 
central cobalt compartment. The (apparent) volume of distribu­
tion in steady-state (Vss) is 48 liters, which may be explained 
by massive accumulation of cobalt in the liver. Our blood- 
partition data of 55Co represent the average values of 20 
samples taken in a period of 300 min postinjection. Although 
there may be some difference in blood partition in relation to 
time, these differences were not statistically significant. The 
cobalt injected into the blood was predominantly retrieved 
attached to leukocytes and plasma protein. Less than 12% of the 
blood cobalt could be recovered from the protein-free plasma. 
Protein precipitation by TCA generated a greater free-fraction 
'recovery than dialysis, suggesting the existence of both diffus­
ible and nondiffusible free-fraction cobalt. The nondiffusible 
free-fraction cobalt actually may be reversibly bound to plasma 
protein, only made available as free cobalt after TCA-mediated 
dissociation from the carrier protein. These results are demon­
strated in other work as well (14).
Assuming a contamination of 2% 56Co, which seems realistic 
in clinical practice, the administration of 55CoCl2 has to be 
limited to 18.5 MBq (0.5 mCi) in order to remain in class II
studies as defined by the WHO. Accordingly, the maximal dose 
of 57Co is 11 MBq (0.3 mCi).
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